These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8666677)

  • 1. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.
    Kitchen S; Jennings I; Woods TA; Preston FE
    J Clin Pathol; 1996 Jan; 49(1):10-4. PubMed ID: 8666677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
    Findlater SH
    Clin Lab Sci; 2012; 25(3):142-8. PubMed ID: 22953513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent.
    Brancaccio V; Ames PR; Glynn J; Iannaccone L; Mackie IJ
    Blood Coagul Fibrinolysis; 1997 Apr; 8(3):155-60. PubMed ID: 9167015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of phospholipid reagents used in coagulation II: factors influencing their sensitivity to heparin.
    Barrowcliffe TW; Gray E
    Thromb Haemost; 1981 Oct; 46(3):634-7. PubMed ID: 7314057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma.
    Zanke B; Shojania AM
    Am J Clin Pathol; 1990 May; 93(5):684-9. PubMed ID: 2183588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The control of heparin therapy by the activated partial thromboplastin time: results of collaborative studies.
    Thomson JM
    Scand J Haematol Suppl; 1980; 37():73-83. PubMed ID: 6941440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin in vitro sensitivity of the activated partial thromboplastin time in canine plasma depends on reagent.
    Mischke R
    J Vet Diagn Invest; 2003 Nov; 15(6):588-91. PubMed ID: 14667026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer.
    Shojania AM; Tetreault J; Turnbull G
    Am J Clin Pathol; 1988 Jan; 89(1):19-23. PubMed ID: 3337049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy.
    Gausman JN; Marlar RA
    Am J Clin Pathol; 2011 Jun; 135(6):870-6. PubMed ID: 21571960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing different lots of activated partial thromboplastin time reagent: analysis of two methods.
    Rosborough TK
    Am J Clin Pathol; 1998 Aug; 110(2):173-7. PubMed ID: 9704615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.
    D'Angelo A; Seveso MP; D'Angelo SV; Gilardoni F; Dettori AG; Bonini P
    Am J Clin Pathol; 1990 Sep; 94(3):297-306. PubMed ID: 2396604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An attempt to standardize the APTT for heparin monitoring, using the P.T. ISI/INR system of calibration. Results of a 13 centre study.
    Reed SV; Haddon ME; Denson KW
    Thromb Res; 1994 Jun; 74(5):515-22. PubMed ID: 8085252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents.
    Gouin-Thibaut I; Martin-Toutain I; Peynaud-Debayle E; Marion S; Napol P; Alhenc-Gelas M;
    Thromb Res; 2012 May; 129(5):666-7. PubMed ID: 22169771
    [No Abstract]   [Full Text] [Related]  

  • 19. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid composition of seven APTT reagents in relation to heparin sensitivity.
    Kitchen S; Cartwright I; Woods TA; Jennings I; Preston FE
    Br J Haematol; 1999 Sep; 106(3):801-8. PubMed ID: 10468876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.